Evidence map›Paper›PMID 35758652›Full record

Trial reportJournal of clinical microbiology2022

Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study.

Alexey Ruzin, Olivier Barraud, Li Yu, Bruno François, Miguel Sánchez-Garcia, Philippe Eggimann, Pierre-François Dequin, Pierre-François Laterre, Vincent Huberlant, Lucia Viña and 19 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 13 institutions in 5 countries.

Alexey Ruzin *Early Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Olivier Barraud *ICU and Inserm CIC-1435 and UMR-1092, Centre Hospitalier Universitaire de Limoges, Limoges, France.ORCID 0000-0003-2015-9206
Li YuStatistical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Bruno FrançoisICU and Inserm CIC-1435 and UMR-1092, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Miguel Sánchez-GarciaHospital Clinico San Carlos, Madrid, Spain.
Philippe EggimannCentre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Pierre-François DequinUniversité François Rabelais, Tours, France.
Pierre-François LaterreSt. Luc University Hospital, Brussels, Belgium.
Vincent HuberlantCentre Hospitalier Jolimont-Lobbes, Lobbes, Belgium.
Lucia ViñaHospital Universitario Central de Asturias, Oviedo, Spain.
Thierry BoulainCentre Hospitalier Régional d'Orléans, Orléans, France.
Cedric BretonniereHôpital Guillaume et René Laennec, Nantes, France.
Jérôme PuginHôpitaux Universitaire de Genève, Geneva, Switzerland.
José TrenadoHospital Mutua de Terrassa, Terrassa, Spain.
Ana Catalina Hernandez PadillaICU and Inserm CIC-1435 and UMR-1092, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Julie VignaudICU and Inserm CIC-1435 and UMR-1092, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Drieke VandammeICU and Inserm CIC-1435 and UMR-1092, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Herman GoossensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerpgrid.5284.b, Antwerp, Belgium.
Christine LammensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerpgrid.5284.b, Antwerp, Belgium.
S Omar AliEarly Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Kathryn ShoemakerLate-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Pin RenLate-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Susan ColbertDevelopment Operations, BioPharmaceuticals R&D, AstraZeneca, Wilmington, Delaware, USA.
Terramika BellamyEarly Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Bret R SellmanEarly Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Michael McCarthyResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Hasan S JafriEarly Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Mark T EsserEarly Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
SAATELLITE Study Group
AstraZeneca (United States) · USInserm · FRUniversity of Antwerp · BECentre hospitalier universitaire d'Orléans · FRHôpital Beau-Séjour · CHHôpital de Jolimont · BEHôpital Laennec · FRHospital Clínico San Carlos · ESHospital Universitario Central de Asturias · ESUCLouvain Saint-Louis Brussels · BEUniversité de Tours · FRUniversity Hospital Mútua de Terrassa · ESUniversity Hospital of Lausanne · CH

Funding

Innovative Medicines Initiative Joint Undertaking 115523
6 · The paper itself

Abstract

We investigated the performance of the Xpert methicillin-resistant Staphylococcus aureus (MRSA)/S. aureus skin and soft tissue (SSTI) quantitative PCR (qPCR) assay in SAATELLITE, a multicenter, double-blind, phase 2 study of suvratoxumab, a monoclonal antibody (MAb) targeting S. aureus alpha-toxin, for reducing the incidence of S. aureus pneumonia. The assay was used to detect methicillin-susceptible S. aureus (MSSA) and MRSA in lower respiratory tract (LRT) samples from mechanically ventilated patients. LRT culture results were compared with S. aureus protein A (

Indexed as

Methicillin-Resistant Staphylococcus aureusSoft Tissue InfectionsStaphylococcal InfectionsHumansReal-Time Polymerase Chain ReactionRespiration, ArtificialStaphylococcus aureusqPCRSAATELLITEStaphylococcus aureussuvratoxumabventilator-associated pneumonia

Identifiers

PMID35758652
PMCPMC9297837
OpenAlexW4283580381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.